Global Dermatology Drugs Market to 2023 – Growth Driven by Increased Uptake of Interleukin Receptor Inhibitors for Psoriasis and Atopic Dermatitis

“The Report Global Dermatology Drugs Market to 2023 – Growth Driven by Increased Uptake of Interleukin Receptor Inhibitors for Psoriasis and Atopic Dermatitis provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. – MarketResearchReports.biz”

About Dermatology Drugs Market

Dermatology is a highly diverse therapy area that deals with diseases of the skin, hair and nails. Over 3,000 types of dermatological conditions are thought to exist, ranging from the autoimmune disorder psoriasis to the very common condition acne vulgaris. The scope of dermatological disorders is diverse in terms of severity and clinical presentation, and if a condition is not sufficiently kept under control, it can significantly impair the patient’s quality of life.

The treatment landscape for dermatological disorders was traditionally dominated by genericized topical therapies such as glucocorticoids and retinoids. The approval of monoclonal antibodies (mAbs) such as Humira, Enbrel and Remicade for psoriasis revolutionized both the management of psoriasis and the dermatology therapy area. These first generation mAbs are now off-patent and have biosimilar versions approved by the FDA, but in recent years the therapy area has seen a number of new mAbs enter the market. These new approvals will provide patients with more treatment options and stimulate growth in the therapy area. In 2017 Dupixent became the first biologic to be approved for atopic dermatitis, expanding the use of biologics to an indication other than psoriasis.

Get Sample copy of this Report @ https://www.marketresearchreports.biz/sample/sample/1287797

Overall there are 871 products being actively developed in the dermatology pipeline, but these include products being developed for many smaller indications. The indications with the largest pipelines are psoriasis, atopic dermatitis and acne vulgaris, which contain 282, 136 and 70 products, respectively.

Scope

Global revenue from the dermatology market is forecast to increase from $19.8 billion in 2016 to $36.6 billion in 2023, at a compound annual growth rate of 9.13%. Which drugs will achieve blockbuster status and how will the key player companies perform during the forecast period?

What are the leading companies in terms of market share?

Which companies are forecast to experience the largest growth in market share?

Which companies rely heavily on revenue derived from antibacterial drugs?

How will the market respond to recent approvals?

Will generics and biosimilars have a significant impact on the market over the forecast period?

What class of drugs dominate the market?

What molecular targets are most popular in the pipeline?

What are the commercial prospects for the most promising late-stage products?

View Sample PDF @

https://www.marketresearchreports.biz/reports/1287797/global-dermatology-drugs-to-market-research-reports.pdf

Reasons to buy

Understand the current treatment landscape, with portfolios of key marketed products and a focus on historical and forecast sales patterns, and an overview of each drug’s mechanism of action.

Analyze the dermatology pipeline through a comprehensive review of the pipeline segmented by stage of development, molecule type and molecular target.

This review also provides a detailed look at dermatology product clinical trials to provide an insight into the risk associated with attempting to bring pipeline products to market.

Predict growth in market size, with in-depth market forecasting from 2016 to 2023. The forecasts will provide an understanding of how epidemiology trends, new drug entries, and patent expirations will influence market value.

Identify commercial opportunities in the dermatology deals landscape by analyzing trends in licensing and co-development deals.”

View Report @

https://www.marketresearchreports.biz/reports/1287797/global-dermatology-drugs-to-market-research-reports

Table of Contents

1 Table of Contents

1 Table of Contents 4

1.1 List of Tables 6

1.2 List of Figures 7

2 Introduction 10

2.1 Therapy Area Introduction 10

2.2 Symptoms 10

2.3 Etiology and Pathophysiology 11

2.3.1 Atopic Dermatitis 11

2.3.2 Acne Vulgaris 13

2.3.3 Psoriasis 14

2.4 Co-morbidities and Complications 14

2.5 Diagnosis, Scales and Grading 15

2.5.1 Atopic Dermatitis 15

2.5.2 Acne Vulgaris 16

2.5.3 Psoriasis 17

2.6 Epidemiology Patterns and Forecasts – Prevalence and Patient Segmentation 17

2.6.1 Atopic Dermatitis 18

2.6.2 Acne Vulgaris 19

2.6.3 Psoriasis 20

2.7 Treatment 21

2.7.1 Topical Corticosteroids 22

2.7.2 Calcineurin Inhibitors 23

2.7.3 Retinoids 23

2.7.4 Systemic Immunosuppressive Agents 24

2.7.5 Biologics 25

2.7.6 Antihistamines 25

2.7.7 Hormonal Therapy 26

2.7.8 Moisturizers 26

3 Key Marketed Products 27

3.1 Overview 27

3.2 Humira (adalimumab) – AbbVie 27

3.3 Remicade (infliximab) – Johnson & Johnson 29

3.4 Enbrel (etanercept) – Amgen 31

3.5 Stelara (ustekinumab) – Johnson & Johnson 33

3.6 Neoral (cyclosporine) – Novartis 34

3.7 Protopic (tacrolimus) – Astellas Pharma 36

3.8 Cosentyx (Secukinumab) – Novartis 37

3.9 Dupixent (dupilumab) Sanofi and Regeneron 39

3.10 Taltz (ixekizumab) – Eli Lilly 41

3.11 Eucrisa (crisaborole) – Pfizer 43

3.12 Siliq (Brodalumab) – Valeant Pharmaceuticals 44

3.13 Elidel (pimecrolimus) 46

3.14 Elocon (mometasone furoate) 46

3.15 Differin (adapalene) 47

3.16 Metolate (methotrexate) 48

3.17 Clobex (clobetasol propionate) 48

3.18 Conclusion 49

4 Pipeline Landscape Assessment 50

4.1 Overview 50

4.2 Molecule Types in the Pipeline 53

4.3 Molecular Targets in the Pipeline 54

4.4 Clinical Trials 56

4.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target 57

4.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target 61

4.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target 65

4.4.4 Aggregate Clinical Program Size by Stage of Development, Indication, Molecule Type and Molecular Target 69

4.4.5 Assessment of Key Pipeline Products 72

4.5 Conclusion 78

Send An Enquiry Request @ https://www.marketresearchreports.biz/sample/enquiry/1287797

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact

Mr. Nachiket

State Tower

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-621-2074

Website: http://www.marketresearchreports.biz/

E: sales@marketresearchreports.biz

Designed by CyFocus.com
Powered by CyFocus.net